PROIECTE DE CERCETARE ȘTIINȚIFICĂ

Centrul pentru Chirurgie Urologică și Transplant Renal de la Institutul Clinic „Fundeni“ a fost acreditat **centru de cercetare** de către Ministerul Educației și Cercetării și Consiliul Național al Cercetării Științifice din Învățământul Superior în martie 2002.

1. **Polimorfisme prezente în profilul genetic al citokinelor implicate în rejetul de grefă şi în producerea infecţiilor virale la pacienţii primitori de transplant**
   Contract: 148/2006. Responsabil Partener, 2006-2008

2. **Studiu clinic şi urodinamic al tulburărilor de continenţă vezicală la copil: evaluare etiologică şi terapeutică**
   Competiţia CEEX, Contract:129/2006. Responsabil Partener, 2006-2008

3. **Răspunsul imun şi semnificaţia prognostică după administrarea de interferon alfa la pacienţii cu cancer renal stadiul metastatic**
   Competiţia de Granturi a Academiei Române – Nr. 224/2007. Director de Proiect, 2007-2009

4. **Bazele celulare şi moleculare ale influenţei modificărilor tubului seminifer asupra fenomenului de îmbătrânire la nivelul testiculului - studiu la om şi experimental (FIBROTESTIS)**
   Competiţia PN2-Parteneriate, Contract 41-015/2008. Responsabil Partener, 2008-2011

5. **Impactul profilului imunohistochimic şi molecular în terapia ţintită şi în managementul individualizat al pacienţilor cu carcinom renal (RENTHER)**
   Competiţia PN2-Parteneriate, Contract 62089/2008
   Director de Proiect, UMF „Carol Davila“ Bucureşti, I.C. „Fundeni“, 2008-2011

6. **Program strategic pentru promovarea inovării în servicii prin educaţie deschisă, continuă (INSEED)** POSDRU-86-1.2/S/57748
   Expert pe termen lung, UMF „Carol Davila“ din Bucureşti și Universitatea Politehnică Bucureşti, 2010-2013

7. **Susţinerea cercetării postdoctorale în domeniul chirurgiei reconstructive de transplant (POSTDOC-Transplant)** POSDRU/89/1.5/S/64153
   Tutore – Expert pe termen lung. UMF „Carol Davila“ din Bucureşti, 2010-2013

8. **CERO – Profil de carieră: Cercetător român**
   POSDRU/159/1.5/S/135760. Director General Centru de Cercetare, UMF „Carol Davila“ din Bucureşti, 2013-2015

9. **Parteneriat pentru o cariera de succes în specialitatile medicale implicate în patologia renală (PERFMED)**
   POSDRU/161/2.1/G/135802
   Manager de Proiect, UMF „Carol Davila“ din Bucureşti, 2013-2015

10. **Inginerie de Mentenanţă pentru ELI-NP ID 142253**
    POSDRU 156/1.2/G/142253
    Coordonator Partener, UMF „Carol Davila“ din Bucureşti și Universitatea Politehnică Bucureşti, 2013-2015

11. **Set de biomarkeri pentru predicţia individualizată a evoluţiei în cancerul de prostată cu risc înalt, bazat pe abordare proteomică şi genomică (PROMETEU),**
    PN-II-PT-PCCA-2013-4-1851.
    Membru în echipă, UMF „Carol Davila“ din Bucureşti, 2014-2016.

STUDII CLINICE NAŢIONALE ŞI INTERNAŢIONALE

1. STUDY CODE: 97-51-O-D-7: „Study to evaluate the efficacy and safety of cyclosporine Hexal in *de novo* renal transplant patients. Open, randomized, controlled phase III trial“ (1999 – 2000).

2. STUDY EGD-EC-003: „A phase III randomised study of intermittent versus continous androgen deprivation therapy using Eligard 22,5 mg, 3 months depot in subject with relapsing and locally advanced prostate cancer who are responsive to such therapy“ (2007 – 2011).

3. STUDY BASTA: „Efficacy of two formulation of *Sabal Serrulata* – a double blind randomised placebo-controlled phase III study“ (2007 – 2009).

4. „A Multi-Center Randomised Double Blind – Placebo Controlled Parallel Group Prospective study to Assess the Efficacy, Safety and Tolerability of three Oral Doses of Netupitant Given Once a Day vs. Placebo in patients with OAB“ (2008 – 2009).

5. „A randomised, double blind parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5 mg) and tamsulosin (0.4 mg) administered once daily for 4 years, alone and in combination, on improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia“ (2005 – 2009).

6. STUDY PROSTAMOL UNO – FLUX: „Studiu clinic multicentric de evaluare a eficacităţii extractului de Serenoa Repens“ (2002 – 2005) (BERLIN-CHEMIE Medical Company).

7. STUDY OSAKA: „A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunossuppressive Regimen In Kidney Transplants Subjects“ (2008 – 2010).

8. STUDY IMPACT 200: „A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients“ (2006 – 2009).

9. STUDY RESTORE: „A Multicentre, Randomized, Open Clinical Study to Compare the Efficacy and Safety of a Combination Therapy of Tacrolimus with Sirolimus versus Tacrolimus with Mycophenolate Mofetil in Kidney Transplantation“ (2005 – 2006).

10. STUDY EQUART „International, Multicenter, Randomized, Comparative Open-Label, Parallel Group Clinical Trial to Evaluate Interchangeability of Equoral® and Sandimun® Neoral® Capsules in Stable Adult Renal Transplant Recipients“ (2002 – 2004).
11. STUDY SCORPIO: „A phase III, randomized double-blind, parallel-group, placebo and active controlled, multi-center study to assess the efficacy and safety of the beta-3 agonist YM 178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder“ (2008 – 2009).
12. STUDY AEZS-102-036: „Centorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study“ (2008 – 2009).
13. STUDY TAURUS: „A phase III, randomized, double-blind, parallel-group, placebo and active controlled, multi-center long-term study to assess the efficacy and safety of the beta-3 agonist YM 178 in subjects with symptoms of overactive bladder“ (2009 – 2010).
14. STUDY TAROK: „Non-interventional survey to document safety and tolerability outcomes that reflect routine clinical use of Advagraf in de-novo liver or kidney transplant recipients in Romania“ (apr. 2010 – 2013).
15. STUDY IC-01-01-4-003: „A phase IIb study – Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multicenter, randomized, parallel-group, placebo-controlled clinical study“ (SUITE study) (2010 – 2011).
16. 9785-CL-0222: „A randomized double-blind phase two, efficacity and safety study of MDV3100 (ASP9785) vs Bicalutamide in castrate men with metastatic prostate cancer“ (2010 – 2014).
17. STUDY ADVANCE: „Advagraf based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients“ (2011 – 2012).
18. STUDY IC-01-01-05-004: „A multicentre, randomized, parallel-group, placebo-controlled study to assess the efficacy and safety of skeletal muscle derived cell implantation in female patients with stress urinary incontinence“ (2012 – 2015).
19. STUDY IC-01-01-05-005: „Skeletal Muscle-Derived Cell Implantation in Female Patients with Stress Urinary Incontinence: A Multinational and Multicenter Open Follow-up study“ (2012 – 2015).
20. XEN-D0501-CL-03: „A phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB) “ (Jul. 2011 – Sept. 2011)
21. KMD 3213 IT-CL 0376 – EUDRACT 2011-000045-20: „Effectiveness and safety of Silodosin in the treatement of LUTS in patients with benign prostatic hyperplasia: A European phase IV for clinical study – The Silodosin in Real-life Evaluation study“ (Jul. 2011 – 2013).
22. ISIS 183750 – CS3: „A phase IIb Study of Docetaxel and Prednison with or without ISIS 183750 (an eIF4E inhibitor) in Patients with Castrate Resistant Prostate Cancer“ (Oct. 2011 – 2013).
23. BRISTOL - SLHN 2010-81 CA 184-095: „Randomized Double Blind Phase III Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients w/Chemo-Naïve Castration Resistant Prostate Cancer“ (2011 – 2012).
24. Proceduri de Operare Standard în Studiile Clinice V 5.0 / 2011.

25. STUDY Prot. No.: 8-55-52014-200: „A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a 3-Month Formulation of Triptorelin Pamoate (11.25 mg) in Patients with Locally Advanced or Metastatic Prostate Cancer“ (EudraCT No. 2012-001279-35) (2012 – 2013).
26. STUDY Prot. No.: CA209025: „A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Carcinoma Who Have Received Prior Anti-Angiogenic Therapy“ (EudraCT No. 2011-005132-26) (2013 – 24.03.2017).
27. STUDY Prot. No.: CXA cUTI-10-04: „A Multicenter, Double-blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA 201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis“ (EudraCT No. 2010-023452-87) (2013 –2015).
28. STUDY ISN/Prot. No.: 3652-CL-0018: „A Phase 2, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Adaptative, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Subjects with Bladder Pain Syndrome / Interstitial Cystitis“ (EudraCT No. 2011-004555-39) (2013 – 2014).
29. STUDY PMR/EC/1213 – „Long term follow-up of patients who were previously enrolled into a Tacrolimus (Advagraf) study following a kideny or liver transplant, a multicenter non-interventional post-authorization study“ (ADDRESS) (2015-2018)
30. STUDY CHORUS – „Urmărirea pe termen lung a adulţilor care au primit alografă pentru rinichi şi ficat anterior înscrişi într-un studiu cu Tacrolimus (Advagraf). Un studiu multicentric non-intervenţional post-autorizare“ (2015-2018)